Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
75317 participants
INTERVENTIONAL
2013-11-30
2014-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Increasing Uptake of Colorectal Cancer Screening in Ontario
NCT01629004
Randomized Trial Evaluating the Effectiveness of the General Practitioner Involvement in Cancer Screening Invitations
NCT02367001
Information About a Doctor or a Possibility of Choosing Doctor's Gender and Attendance to Screening Colonoscopy
NCT01182922
Time Schedules for Sending Invitations to Colonoscopy Screening
NCT01505972
Social Media for Colorectal Cancer Screening
NCT04296630
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A central tenet of organized screening programs is that all persons in the target population be invited to participate. In 2010, CCC began implementing a correspondence program in an effort to improve participation in colorectal cancer screening, starting with recall letters to individuals who were due for repeat screening two years after a normal fecal occult blood test (FOBT) and invitation letters to screen-eligible individuals who are due for screening and have not received correspondence from CCO to participate in colorectal cancer screening in the past two years to complete a screening test for colorectal cancer. Individuals who are "due for screening" includes those who have not had a FOBT in the past 2 years, a flexible sigmoidoscopy in the past 5 years, and a colonoscopy in the past 10 years. Currently, CCC sends 10,000 invitation letters monthly to 50-54 year olds only. In October 2013, the CCC correspondence program expanded to also include all eligible Ontarians 55-74 years old.
The current CCC invitation letter includes general information on the benefits of screening for colorectal cancer, the screening test itself (FOBT), and contact information to get more information. It is meant to invite individuals to speak with their primary care provider about colorectal screening. In 2013 Diego Llovet, a lead qualitative researcher at CCO, completed a series of qualitative studies examining the content of current CCC correspondence materials and made recommendations to improve the content of invitation letters. These recommendations were based on four key types of information: a) findings from seven focus groups with screen-eligible Ontarians (men and women, 50-74) who provided feedback on the messages that should be included in these letters, b) input provided by six experts in health communications and health promotion on the content and style of effective cancer screening correspondence, c) evidence from behavioral science studies on barriers to participation in colorectal cancer screening, and d) theories of health behavior change. Based on findings from focus group studies examining the content of the current CCC letter, a unisex and a male-tailored invitation letter were developed. A female-tailored letter was not developed as the focus group studies with females showed that they did not prefer female tailored messaging to a unisex one.
In the current study, we propose to test the effectiveness of mailed invitations for colorectal cancer screening in the real world setting of the CCC program. We will evaluate the effectiveness of mailed invitations in general (i.e., compared to no invitation) but we will also determine whether letters developed based on theories from behavioural science and on the results of qualitative studies with Ontarians in the target population are more effective than those currently used by the program. The findings from this study will be used to inform the CCC program correspondence but will also provide valuable information for the development of correspondence for other screening programs at Cancer Care Ontario and in other jurisdictions engaged in organized screening programs.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
FACTORIAL
SCREENING
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Male arm
Males control group: Deferred letter Males Group 1: Current CCC invitation letter Males Group 2: New letter with neutral gender content Males Group 3: New letter with male-specific content
Males control group: Deferred letter
This letter will be sent 6 months after index (mailing) date
Males Group 1: Current CCC invitation letter
This letter is currently used by the program in 50-54 year olds
Males Group 2: New letter with neutral gender content
Unisex letter
Males Group 3: New letter with male-specific content
New letter tailored for men
Female arm
Females control group: Deferred letter Females Group 1: Current CCC invitation letter Females Group 2: New letter with neutral gender content
Females control group: Deferred letter
This letter will be sent 6 months after index (mailing) date
Females Group 1: Current CCC invitation letter
This letter is currently used by the program in 50-54 year olds
Females Group 2: New letter with neutral gender content
Unisex letter
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Males control group: Deferred letter
This letter will be sent 6 months after index (mailing) date
Males Group 1: Current CCC invitation letter
This letter is currently used by the program in 50-54 year olds
Males Group 2: New letter with neutral gender content
Unisex letter
Males Group 3: New letter with male-specific content
New letter tailored for men
Females control group: Deferred letter
This letter will be sent 6 months after index (mailing) date
Females Group 1: Current CCC invitation letter
This letter is currently used by the program in 50-54 year olds
Females Group 2: New letter with neutral gender content
Unisex letter
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Withdrawn from program correspondence
* Prior colorectal cancer diagnosis
* Any FOBT activity within the last two years, including
* Flexible sigmoidoscopy within the last five years.
* Colonoscopy within the last ten years
* Other medical history in the last 30 months
* Exclusion from screening in the last 30 months
* Received a birthday letter, invitation or recall within the last two years
* Inactive primary address
* Missing address
* Address outside Ontario
55 Years
74 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Cancer Care Ontario
OTHER
Sunnybrook Health Sciences Centre
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jill Tinmouth, MD PhD FRCPC
Role: PRINCIPAL_INVESTIGATOR
Sunnybrook Health Sciences Centre, Cancer Care Ontario
References
Explore related publications, articles, or registry entries linked to this study.
Tinmouth J, Llovet D, Sutradhar R, Tsiplova K, Roushani J, Lee A, Hader J, Rabeneck L, Paszat L. Two randomized controlled trials for colorectal cancer screening invitations developed using a behavioral science approach. Prev Med. 2022 Feb;155:106918. doi: 10.1016/j.ypmed.2021.106918. Epub 2021 Dec 23.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
375-2013
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.